Annals Internal Medicine, Author Interviews, Herpes Viruses, HIV / 01.07.2014
Oral HIV Prophylaxis May Also Provide Some Protection Against Herpes
MedicalResearch.com: Interview with
Connie Celum, MD, MPH
Professor of Global Health and Medicine
Director, International Clinical Research Center
University of Washington
Harborview Medical Center
Seattle WA 98104
MedicalResearch: What are the main findings of the study?
Dr. Celum: We conducted a randomized, double blind study of daily oral tenofovir and tenofovir combined with emtricitabine (FTC) as oral pre-exposure prophylaxis (PrEP) for HIV among HIV serodiscordant couples (in which onepartner had HIV and the other partner did not) in Kenya and Uganda. Because of recent studies showing that tenofovir gel could reduce the chances of becoming HSV-2 infected, we studied the subset of HIV-uninfected partners who did not have HSV-2 and compared the rates who became HSV-2 infected during follow-up among those who received oral pre-exposure prophylaxis versus those who received placebo. We found that oral pre-exposure prophylaxis reduced HSV-2 acquisition by 30%.
